Saltar al contenido principal
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

Observacional1350 participantes buscados47 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Afecciones

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo
Método de muestreoNON_PROBABILITY_SAMPLE

Población del estudio

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Elegibilidad tal como figura en el registro

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioObservacional
FaseNo indicado en el registro
AsignaciónNo indicado en el registro
Modelo de intervenciónNo indicado en el registro
Propósito principalNo indicado en el registro
EnmascaramientoNo indicado en el registro
Inscripción1350 participantes buscados

Patrocinador y colaboradores

  • Paradigm Health Patrocinador

Grupos e intervenciones

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

Intervenciones

  • Prueba diagnóstica blood and tissue samples

    routine standard of care

  • Otro blood and tissue samples

    Routine standard of care

Variables de resultado

  1. Variable de resultado principal

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    Plazo Observation from enrollment to 5.5 years after enrollment

Fechas

Fechas
Fecha de inicio8 de enero de 2025 (real)
Finalización principal1 de diciembre de 2031 (estimada)
Finalización1 de abril de 2032 (estimada)
Primera publicación20 de septiembre de 2024 (real)
Última actualización24 de septiembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezseptiembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

47 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Piedmont Cancer InstituteAtlantaGeorgiaEn reclutamiento
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew YorkEn reclutamiento
Alabama OncologyBirminghamAlabamaEn reclutamiento
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaEn reclutamiento
Gabrail Cancer CenterCantonOhioEn reclutamiento
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaEn reclutamiento
Carolina Oncology SpecialistsCharlotteNorth CarolinaEn reclutamiento
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaEn reclutamiento
Baptist Health CorbinCorbinKentuckyEn reclutamiento
Pontchartrain Cancer CenterCovingtonLouisianaEn reclutamiento
Baptist Health HardinElizabethtownKentuckyEn reclutamiento
The Melanoma and Skin Cancer InstituteEnglewoodColoradoEn reclutamiento
San Juan Oncology AssociatesFarmingtonNew MexicoEn reclutamiento
Los Angeles Cancer Network (LACN)GlendaleCaliforniaEn reclutamiento
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth CarolinaEn reclutamiento
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganEn reclutamiento
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasEn reclutamiento
Community Clinical TrialsKingwoodTexasEn reclutamiento
Lancaster General Hospital (UPenn)LancasterPennsylvaniaEn reclutamiento
Baptist Health LexingtonLexingtonKentuckyEn reclutamiento
Cancer Partners of NebraskaLincolnNebraskaEn reclutamiento
CARTILittle RockArkansasEn reclutamiento
Baptist Health LouisvilleLouisvilleKentuckyEn reclutamiento
Taylor Cancer Research CenterMaumeeOhioEn reclutamiento
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisEn reclutamiento
Mid Florida Cancer CentersOrange CityFloridaEn reclutamiento
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaEn reclutamiento
Oregon Health & Science University (OHSU)PortlandOregonEn reclutamiento
Virginia Cancer InstituteRichmondVirginiaEn reclutamiento
Mayo ClinicRochesterMinnesotaEn reclutamiento
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaEn reclutamiento
Medical Oncology Associates of San DiegoSan DiegoCaliforniaEn reclutamiento
Guthrie FoundationSayrePennsylvaniaEn reclutamiento
New York Cancer & Blood SpecialistsShirleyNew YorkEn reclutamiento
Christus Health HighlandsShreveportLouisianaEn reclutamiento
Highlands Oncology Group (HOG)SpringdaleArkansasEn reclutamiento
Cox HealthSpringfieldMissouriEn reclutamiento
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaEn reclutamiento
Stockton Hematology Oncology Med GroupStocktonCaliforniaEn reclutamiento
Northwest Medical Specialties (NWMS)TacomaWashingtonEn reclutamiento
Christus St. Michael'sTexarkanaTexasEn reclutamiento
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasEn reclutamiento
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaEn reclutamiento
Carle HealthUrbanaIllinoisEn reclutamiento
Cancer Center of KansasWichitaKansasEn reclutamiento
Regional Medical Oncology CenterWilsonNorth CarolinaEn reclutamiento
Cancer Care Associates of York (CCAY)YorkPennsylvaniaEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 24 de septiembre de 2026

    Centro añadido

    45 sites added (47 total)

    247